Table 5 Role played by antiplatelet and anticoagulant therapy, alone and combined, on recurrence and mortality in patients with haemoptysis
From: Long-term prognostic outcomes in patients with haemoptysis
Antiplatelet and anticoagulant therapy | No | Yes | p-value |
|---|---|---|---|
Recurrence, n (%) | 68 (20.1) | 35 (18.8) | 0.72 |
Recurrence severity, n (%) | |||
Mild | 49 (72.1) | 25 (71.4) | 0.46 |
Moderate | 17 (25.0) | 7 (20.0) | |
Severe | 2 (2.9) | 3 (8.6) | |
Median (IQR) n. recurrence events | 1 (1–2) | 1 (1–2) | 0.12 |
Deaths after 18 months of follow-up, n (%) | 50 (12.6) | 33 (16.0) | 0.24 |
Deaths for the disease which caused haemoptysis, n (%) | 31 (62.0) | 21 (63.6) | 1.00 |
Antiplatelet therapy | |||
Recurrence, n (%) | 80 (20.2) | 23 (18.0) | 0.58 |
Recurrence severity, n (%) | |||
Mild | 59 (73.8) | 15 (65.2) | 0.16 |
Moderate | 19 (23.8) | 5 (21.7) | |
Severe | 2 (2.5) | 3 (13.0) | |
Median (IQR) n. recurrence events | 1.5 (1–2) | 1 (1–2) | 0.04 |
Deaths after 18 months of follow-up, n (%) | 60 (13.0) | 23 (16.0) | 0.37 |
Deaths for the disease which caused haemoptysis, n (%) | 35 (58.3) | 17 (73.9) | 0.19 |
Anticoagulant therapy | |||
Recurrence, n (%) | 91 (19.7) | 12 (19.7) | 0.98 |
Recurrence severity, n (%) | |||
Mild | 64 (70.3) | 10 (83.3) | 0.85 |
Moderate | 22 (24.2) | 2 (16.7) | |
Severe | 5 (5.5) | 0 (0.0) | |
Median (IQR) n. recurrence events | 1 (1–2) | 2 (1–2) | 0.66 |
Deaths after 18 months of follow-up, n (%) | 71 (13.2) | 12 (18.5) | 0.24 |
Deaths for the disease which caused haemoptysis, n (%) | 47 (66.2) | 5 (41.7) | 0.10 |